November 19, 2019 IT'S OFFICIAL: As of today,

November 19, 2019
IT'S OFFICIAL: As of today, NexTech AR (OTC: NEXCF) is now up massive +357% since debut at Wall Street Reporter's Next Super Stock conference August 15, 2019.

(AND....NEXCF has almost DOUBLED, just since last week's follow-up "Next Super Stock" conference presentation)

Today, on major news, NEXCF has broken the shackles of gravity, and reached ESCAPE VELOCITY....with almost 1 millions shares volume trading today (record high and record volume), entering official "SUPER STOCK" status...

Check out NEXCF's recent NEXT SUPER STOCK conference presentation, and see what's next for this dynamic company.

WINNERS like NEXCF - is exactly what Wall Street Reporter's NEXT SUPER STOCK conference is all about - we showcase stocks which have 10X upside potential.



In case you missed, last week's NEXT SUPER STOCK livestream, click here for the video replay.

As you can see by these results, there is a good reason THOUSANDS of institutional and savvy individual investors participate and follow the NEXT SUPER STOCK conference presentations.


Click here to check out the on-demand video of the conference presentations


SAVE THE DATE:
DECEMBER 19, 2019 - NEXT SUPER STOCK Livestream
NEWSMAKERS
CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies NexTechAR (OTC: NEXCF) Teams with LivePerson (NASDAQ: LPSN) to Personalize Augmented Reality Through Conversational Commerce Hoth Therapeutics (NASDQ: HOTH) to Attend Benchmark’s 8th Annual Discovery 1×1 Conferenc NexTech (OTC: NEXCF) Expands AR Deal With Challenger Motor Freight Inc. Hoth Therapeutics (NASDAQ: HOTH) Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication CytoDyn (OTC: CYDY) Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer